Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59.

Google Scholar 

World Health Organization. Atlas of headache disorders and resources in the world 2011. Geneva: World Health Organization; 2011.

Google Scholar 

Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.

Viana M, Sances G, Linde M, et al. Prolonged migraine aura: new insights from a prospective diary-aided study. J Headache Pain. 2018;19(1):77.

PubMed  PubMed Central  Google Scholar 

Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622.

PubMed  PubMed Central  Google Scholar 

Moreno-Ajona D, Pérez-Rodríguez A, Goadsby PJ. Small-molecule CGRP receptor antagonists: a new approach to the acute and preventive treatment of migraine. Med Drug Discovery. 2020;7:100053.

Google Scholar 

Joyner KR, Morgan KW. Novel therapies in acute migraine management: small-molecule calcitonin gene-receptor antagonists and serotonin 1F receptor agonist. Ann Pharmacother. 2021;55(6):745–59.

CAS  PubMed  Google Scholar 

Scott LJ. Ubrogepant: first approval. Drugs. 2020;80(3):323–8.

PubMed  PubMed Central  Google Scholar 

Moreno-Ajona D, Villar-Martínez MD, Goadsby PJ. New generation gepants: migraine acute and preventive medications. J Clin Med. 2022;11(6):1656.

CAS  PubMed  PubMed Central  Google Scholar 

Scott LJ. Rimegepant: first approval. Drugs. 2020;80(7):741–6.

CAS  PubMed  Google Scholar 

Hutchinson S, Pavlovic J, Ailani J, et al. Rimegepant for the acute and preventive treatment of migraine in women: results from 4 randomized, placebo-controlled clinical trials (P9–12007). Neurology. 2003;100(17 Supplement 2):4413.

Google Scholar 

Baker TE, Croop R, Kamen L, et al. Human milk and plasma pharmacokinetics of single-dose rimegepant 75 mg in healthy lactating women. Breastfeed Med. 2022;17(3):277–82.

CAS  PubMed  PubMed Central  Google Scholar 

Deeks ED. Atogepant: first approval. Drugs. 2022;82(1):65–70.

CAS  PubMed  Google Scholar 

Product monograph. QULIPTA®atogepant tablets. https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/QULIPTA_PM_EN.pdf. 2023. Accessed Oct 2024.

Dhillon S. Zavegepant: first approval. Drugs. 2023;83(9):825–31.

PubMed  PubMed Central  Google Scholar 

Martin V, Hoekman J, Aurora SK, Shrewsbury SB. Nasal delivery of acute medications for migraine: the upper versus lower nasal space. J Clin Med. 2021;10(11):2468.

CAS  PubMed  PubMed Central  Google Scholar 

Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142–9.

CAS  PubMed  Google Scholar 

Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737–45.

CAS  PubMed  Google Scholar 

Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51–60.

CAS  PubMed  Google Scholar 

Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230–41.

CAS  PubMed  Google Scholar 

Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887–98.

CAS  PubMed  PubMed Central  Google Scholar 

Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385(8):695–706.

CAS  PubMed  Google Scholar 

Lipton RB, Croop R, Stock DA, et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023;22(3):209–17.

CAS  PubMed  Google Scholar 

Edvinsson L. The CGRP pathway in migraine as a viable target for therapies. Headache. 2018;58(Suppl 1):33–47.

PubMed  Google Scholar 

Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. 2015;80(2):193–9.

CAS  PubMed  PubMed Central  Google Scholar 

Edvinsson L. Calcitonin gene-related peptide (CGRP) is a key molecule released in acute migraine attacks-successful translation of basic science to clinical practice. J Intern Med. 2022;292(4):575–86.

CAS  PubMed  PubMed Central  Google Scholar 

Benarroch EE. CGRP: sensory neuropeptide with multiple neurologic implications. Neurology. 2011;77(3):281–7.

CAS  PubMed  Google Scholar 

Messlinger K, Russo AF. Current understanding of trigeminal ganglion structure and function in headache. Cephalalgia. 2019;39(13):1661–74.

PubMed  Google Scholar 

Close LN, Eftekhari S, Wang M, Charles AC, Russo AF. Cortical spreading depression as a site of origin for migraine: role of CGRP. Cephalalgia. 2019;39(3):428–34.

PubMed  Google Scholar 

Altamura C, Brunelli N, Marcosano M, Fofi L, Vernieri F. Gepants — a long way to cure: a narrative review. Neurol Sci. 2022;43(9):5697–708.

PubMed  PubMed Central  Google Scholar 

Tringali G, Navarra P. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis. Peptides. 2019;116:16–21.

CAS  PubMed  Google Scholar 

Gingell JJ, Hendrikse ER, Hay DL. New insights into the regulation of CGRP-family receptors. Trends Pharmacol Sci. 2019;40(1):71–83.

CAS  PubMed  Google Scholar 

Doods H, Arndt K, Rudolf K, Just S. CGRP antagonists: unravelling the role of CGRP in migraine. Trends Pharmacol Sci. 2007;28(11):580–7.

CAS  PubMed  Google Scholar 

Karsan N, Goadsby PJ. New oral drugs for migraine. CNS Drugs. 2022;36(9):933–49.

CAS  PubMed  PubMed Central  Google Scholar 

Woodhead JL, Siler SQ, Howell BA, Watkins PB, Conway C. Comparing the liver safety profiles of 4 next-generation CGRP receptor antagonists to the hepatotoxic CGRP inhibitor telcagepant using quantitative systems toxicology modeling. Toxicol Sci. 2022;188(1):108–16.

CAS  PubMed  PubMed Central  Google Scholar 

Zobdeh F, Ben Kraiem A, Attwood MM, et al. Pharmacological treatment of migraine: drug classes, mechanisms of action, clinical trials and new treatments. Brit J Pharmacol. 2021;178(23):4588–607.

CAS  Google Scholar 

American Migraine Foundation. Lifestyle changes for migraine management. https://americanmigrainefoundation.org/resource-library/lifestyle-changes-for-migraine/. 2021. Accessed Oct 2023.

Diener H-C. The risks or lack thereof of migraine treatments in vascular disease. Headache J Head Face Pain. 2020;60(3):649–53.

Google Scholar 

Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338–50.

CAS  PubMed  Google Scholar 

Ailani J, Gandhi P, Lalla A, et al. Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine. Headache. 2024;64(10):1253–63.

PubMed  Google Scholar 

Laohapiboolrattana W, Jansem P, Anukoolwittaya P, et al. Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis. J Headache Pain. 2024;25(1):194.

CAS  PubMed  PubMed Central  Google Scholar 

Yang C-P, Liang C-S, Chang C-M, et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(10):e2128544.

PubMed  PubMed Central